Ipsen : Valorisation vs newsflow : le dilemme – OC ajusté à 83.3 € vs 90 €
>Palovarotène : l’électrochoc ? - Début décembre, la FDA a demandé à Ipsen de suspendre les essais cliniques de palovarotène (produit repris début 2019 à Clementia), portant sur les populations pédiatriques (enfants <14 ans) en raison de fermeture précoce du cartilage de croissance observée sur de nombreux patients enfants.Cette annonce intervient 9 mois après l’acquisition de Clementia, 1 mois après le remplacement de Directeur de la R&D, et à un trimestre du dé...Ipsen is global biotechnology specialty care company. Co. engages in research, development, manufacture and sale of pharmaceutical products for human healthcare. Co.'s product portfolio includes pharmaceutical products marketed around the world to specialists working in its targeted therapeutic areas (oncology, endocrinology, neurology and haematology). These products are specialist care drugs. Co. also markets products in other therapeutic areas including gastroenterology, cardiovascular and cognitive disorders. These products are primary care drugs. Co.'s brand names include Decapeptyl®, Somatuline®, Dysport®, Nutropin Aq®, Smecta®, Forlax®, Nisis®,Adrovance®, Exforge® and Adenuric®.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.